Weight-Loss Drug Zepbound May Work Better in Women Than Men - HealthDay
Zepbound, an injectable weight-loss drug, shows better efficacy in women, with up to 25% weight loss compared to 19% in men. Tirzepatide, the active ingredient, consistently reduced weight in both sexes, but more research is needed to understand why women experience greater weight reduction.
Reference News
Zepbound, an injectable weight-loss drug, showed better efficacy in women, with up to 25% weight loss compared to 19% in men. Tirzepatide, the active ingredient, consistently reduced weight in both genders, mimicking hormones GLP-1 and GIP. More research is needed to understand the gender-specific effects.
Tirzepatide, a GIP/GLP-1 receptor agonist, significantly reduces weight in adults with obesity, with women losing more weight (up to 24.6%) than men (up to 18.1%). This sex-based difference in response was observed across SURMOUNT clinical trials, highlighting the need for further research into potential mechanisms and personalized treatment plans.
Zepbound, an injectable weight-loss drug, shows better efficacy in women, with up to 25% weight loss compared to 19% in men. Tirzepatide, the active ingredient, consistently reduced weight in both sexes, but more research is needed to understand why women experience greater weight reduction.